Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as long-COVID, is a
syndrome that describes the persistence of symptoms or other sequelae weeks or months
after initial SARS-CoV-2 infection. Limited evidence exists for effective treatments for
this syndrome.

In this observational study, the investigators will examine the effects of Apollo
wearable use on symptoms and quality of life related to long-COVID. The Apollo
Neuroscience System (combined wearable and mobile application) offers a convenient,
non-invasive, non-habit-forming wearable solution to improve performance and recovery
under stress in children and adults. Our sample will be composed of new purchasers of
Apollo or previous users of Apollo who haven't used Apollo in the preceding 14 days who
are currently experiencing symptoms related to long-COVID according to PASC (self
report).

Clinically validated survey tools will be administered upon enrollment in the study to
assess baseline symptoms and quality of life. Once consented and enrolled in the study,
participants will complete 7 monthly surveys for 6 months. Usage data from subjects' use
of the wearable is also saved on the wearable directly and periodically uploaded to
Apollo Neuroscience's secure and confidential database to be stored for analysis.
Participants will first complete a screener survey to assess eligibility to participate.
Demographic information and medication, substance, and treatment usage will also be
collected.

Participants may choose to provide biometric data at their discretion for purposes of
comparison at least 8 weeks before the study period, during the study period for 6
months, and at most 8 weeks after the study period. With regular Apollo use, the
investigators expect to see an improvement in the physical, cognitive, and psychological
symptoms associated with PASC. Initial analysis will compare subjects' baseline scores
before Apollo use to scores during/after Apollo and the scores of subjects who used
Apollo according to the study protocol and the scores of those who did not. Information
gained from this study will help evaluate the use of Apollo as a potential non-invasive
and accessible solution to aid in reducing long-COVID symptoms.